1. Home
  2. SLGB vs NEUP Comparison

SLGB vs NEUP Comparison

Compare SLGB & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Logistics Global Limited Ordinary Shares

SLGB

Smart Logistics Global Limited Ordinary Shares

N/A

Current Price

$0.32

Market Cap

23.3M

Sector

Industrials

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.80

Market Cap

20.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLGB
NEUP
Founded
2017
1996
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Integrated Freight & Logistics
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
20.6M
IPO Year
2023
2002

Fundamental Metrics

Financial Performance
Metric
SLGB
NEUP
Price
$0.32
$3.80
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
318.0K
49.1K
Earning Date
05-16-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$3.19
52 Week High
$6.02
$21.31

Technical Indicators

Market Signals
Indicator
SLGB
NEUP
Relative Strength Index (RSI) 33.31 49.44
Support Level N/A $3.80
Resistance Level $0.56 $4.15
Average True Range (ATR) 0.04 0.10
MACD -0.01 -0.00
Stochastic Oscillator 12.50 33.90

Price Performance

Historical Comparison
SLGB
NEUP

About SLGB Smart Logistics Global Limited Ordinary Shares

Smart Logistics Global Ltd is a contract logistics solution provider in the PRC. The company focuses on industrial raw materials line-haul transportation business. The group focuses on developing a road-transport smart logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: